GPCR-Targeting Therapeutics
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
49
NCT06617546
SAD and MAD Study of FTX-101 in Healthy Male Subjects
Phase: Phase 1
Role: Lead Sponsor
Start: Oct 14, 2024
Completion: Apr 17, 2025
Loading map...